Alpha thalassemia/mental retardation X-linked (ATRX) protein expression in human pituitary neuroendocrine tumours and its reported correlation to prognosis and clinical outcomes: A systematic review.

Edward Wang[1*], Fabio Rotondo[2], Michael D. Cusimano[1,3]

[1]Department of Surgery, Division of Neurosurgery, St. Michael's Hospital; Injury Prevention Research Office, Li Ka Shing Knowledge Institute, Keenan Research Centre; University of Toronto; Toronto, Canada

[2]Department of Laboratory Medicine, Division of Pathology, Unity Health Toronto- St. Michael's Hospital, Toronto, ON, Canada

[3]Dalla Lana School of Public Health, University of Toronto, Toronto, Canada

*Corresponding author

Email: ewang242@uwo.ca (EW)

Abstract

Mutations in Alpha thalassemia/mental retardation X-linked (ATRX) have been implicated in several cancers, including gliomas, sarcomas, neuroendocrine tumors, and other mesenchymal malignancies. ATRX loss contributes to oncogenesis, accelerates tumor growth, and reduces survival by disrupting epigenetic and telomere mechanisms. Additionally, ATRX loss can increase tumor sensitivity to treatment therapies. While research has explored ATRX expression in many cancers, data on its relationship to prognosis in pituitary neuroendocrine tumors (PitNETs) remain inconsistent. This systematic review aims to summarize all available studies on ATRX mutations and expression in PitNETs. A systematic search of PubMed, Scopus, and EMBASE databases was conducted to identify publications between 2014 and 2025 that investigated ATRX mutations or expression in PitNETs, following PRISMA 2020 guidelines. Of 32 identified studies, ten met the inclusion criteria, covering a total of 513 PitNETs. Only 20 tumors (3.9%) showed a loss of ATRX expression. Among these, 60% exhibited corticotropic pathology, while 20% displayed lactotrophic pathology. A small subset of tumors (30%) was classified as pituitary carcinomas with aggressive and proliferative characteristics. Additionally, 10% demonstrated the alternative lengthening of telomeres (ALT) phenotype, 50% had concurrent TP53 mutations, and 25% had elevated Ki-67 indices, indicating a higher proliferative index. Although ATRX mutations are rare in PitNETs, tumors with ATRX loss tend to be more aggressive and exhibit proliferative and transformative properties. Due to the limited number of cases, further studies with larger, prospective cohorts are needed to better understand the role of ATRX loss in PitNET progression and aggressiveness.

Introduction

Alpha thalassemia/mental retardation X-linked (ATRX) is an ATP-dependent chromatin remodelling protein within the switch/sucrose nonfermentable (SWI/SNF) family of chromatin remodelling proteins. ATRX features two conserved domains: an ATRX-DNMT3-DNMT3L (ADD) domain at the N-terminus and a SNF2 ATPase/helicase domain at the C-terminus. The ADD domain contains critical structures for chromatin localization and binding, housing a GATA-like domain and a PHD-like domain [1]. In neuronal cells, a MECP2 binding domain found within the ATPase domain drives recruitment of ATRX to heterochromatin targets. The ATP-dependent helicase domain is characteristic of other SNF chromatin remodeling proteins and enables functional activity of ATRX (Fig 1) [2]. Germline mutations in these domains are associated with the development of ATR-X syndrome, from which the protein derives its name [1].

Fig 1. Schematic representation of the ATRX protein showing its major functional domains. The N-terminal ADD domain, containing GATA-like and PHD-like domains, mediates chromatin localization and binding [1,2]. A neuronal MECP2 (nMECP2) binding domain provides an alternative route for ATRX recruitment to chromatin targets [2]. The unstructured central region harbors "SDT-like" domains, which modulate MRN activity, and a DAXX-binding domain essential for DAXX-mediated heterochromatin regulation [3]. Towards the C-terminus, the SNF2 ATPase/helicase domain promotes chromatin remodeling. Additional features include an EZH2 domain, which supports PRC2-associated histone methylation, and an HP1α binding domain, facilitating heterochromatin recognition and PML nuclear body interactions [1,2].

ATRX also contains three other domains critical to its function: (1) an enhancer of zeste

homolog 2 (EZH2) binding domain, which includes an HP1α binding domain, (2) several central

"SDT-like" domains within the unstructured central region of the protein, and (3) a death

domain-associated protein (DAXX) binding domain. The ATRX/EZH2 complex is recruited to a

larger polycomb repressive complex 2 (PRC2) to modulate trimethylation of H3K27 (H3K27me3)

, silencing genes surrounding the modified histone (Fig 2). This function is utilized in

transcription regulation as early as embryonic development, where ATRX is involved in X-

chromosome inactivation [1,2]. The ATRX/DAXX complex localizes to promyelocytic leukemia

nuclear bodies (PML-NBs), subnuclear multiprotein structures involved in gene expression,

chromatin regulation, and DNA repair [2,4,5]. ATRX/DAXX modulates the deposition of histone

H3.3 at guanine-rich heterochromatin regions with highly repetitive elements, including

telomeres and pericentromeric regions [1,5–7]. HP1α facilitates ATRX/DAXX preferential

recognition and binding to H3K9me3, facilitating histone H3.3 deposition and maintenance of

heterochromatin integrity [5,8,9]. The SDT-like domains consist of spaced repeats of Ser-X-Thr

motifs, where X is either Asp or Glu. When phosphorylated, these SDT-like domains enable ATRX

to interact with the MRE11-RAD50-NBS1 (MRN) complex, a necessary interaction for ATRX-

mediated DNA damage response (DDR) for double-stranded breaks (DSBs) and stalled

replication forks [2,3]. ATRX sequesters MRN from telomeres, preventing aberrant DDR

activation and preserving telomere stability (Fig 2).

Fig 2. Overview of known molecular pathways of ATRX. The ATRX/DAXX complex localizes to

PML nuclear bodies, where it is recruited to telomeres, pericentromeric heterochromatin, and

other DNA repeat regions. This recruitment is facilitated by HP1α, which recognizes H3K9me3

marks, allowing ATRX/DAXX to deposit histone H3.3 and maintain heterochromatin integrity

[1,2,5,8,9]. ATRX also forms a complex with EZH2 and is incorporated into the larger PRC2

complex, interacting with Xist lncRNA to promote X chromosome inactivation during early

female embryonic development [1,2]. In addition, ATRX sequesters the MRN complex from

telomeric regions, preserving telomere stability [2]. Beyond its role in heterochromatin

maintenance, ATRX modulates replacement of histone macroH2A from gene loci, thereby

maintaining a euchromatic state at target genes, including those encoding α-globin and

tankyrase, and thus supporting their transcription. ATRX is also implicated in the DNA damage

response at stalled replication forks through multiple mechanisms. It indirectly reduces

telomere cohesion and telomere sister chromatid exchanges (T-SCEs) by regulating tankyrase,

which in turn decreases transcription of TERRA, a long noncoding RNA (lncRNA) originating

from telomeric DNA. Excess TERRA promotes secondary structures such as G-quadruplexes (G4)

and R-loops that can stall replication forks [2,10–15]. ATRX helps sequester TERRA and

participates in resolving these secondary structures, although its precise mechanism of action

remains to be fully elucidated. Influenced and adapted from [1,2]

Beyond its role in DNA repair and gene silencing, ATRX also facilitates transcription of

key genes, including α-globin, a protein essential for hemoglobin function, and tankyrase, a

group of enzymes belonging to the poly(ADP-ribose) polymerase (PARP) superfamily. Impaired

α-globin transcription is associated with presentation of α-thalassemia, and in germline

situations, ATR-X (Fig 3) [10–12]. Tankyrase inhibits telomere cohesion and recombination

between sister telomeres, which if allowed to progress, destabilize telomeres and promote

aberrant transcription. The resulting transcripts form the long noncoding RNA (lncRNA) TERRA,

which can hybridize to other genomic regions and induce the formation of G-quadruplexes (G4)

and R-loops (Fig 2). Impaired transcription of tankyrase may prevent proper resolution of these

secondary structures, leading to stalled replication forks error-prone DDR pathways [2,13–15].

Fig 3. Summary of the effects of ATRX mutations on disease, tumors, and development.

Mutations in conserved ATRX domains impair α-globin transcription, leading to α-thalassemia.

Germline mutations of these domains induce the development of ATR-X syndrome. Mutations

to ATRX in gliomas have been observed to inhibit production of DRG2 and RPRM, proteins

critical for regulation of the G2M checkpoint [2,16,17]. IDH1^{R132H}+ gliomas with ATRX mutations

exhibit BRD3/4-dependent immune escape, which involves elevated PD-L expression and

increased production of cytokines. including but not limited to CXCL, CSF2, IL-6, IL-8, and IL-33.

This culminates with increased recruitment of M2 macrophages and T-cell exhaustion,

facilitating immune escape [1,18,19]. ATRX loss increases dsRNA production, activating a

signaling cascade through RIG1, MDA-5, STAT1, and ISG15 that boosts type I interferon and

cytokine output, ultimately enhancing recruitment of CD3+ and CD4+ T cells and increasing

innate immunity sensitization [1,18]. Disruption of ATRX/EZH2 complex formation reduces

suppression of FADD production, allowing FADD-mediated PARP sequestration and heightening

sensitivity to temozolomide (TMZ) [2,20,21]. In PanNETs, ATRX-DAXX-MEN1 (A-D-M) mutations

hypermethylate CpG islands at PDX1 gene loci, compromising β-cell function [1,2,22]. Loss of

ATRX is also a common driver of the ALT (alternative lengthening of telomeres) phenotype,

which features APB (ALT-associated PML bodies) formation, increased telomeric sister

chromatid exchanges (T-SCEs), accumulation of extrachromosomal C-circles, and heightened

TERRA-induced G-quadruplex and R-loop formation [1,2,13–15]. Finally, ATRX dysfunction has

been proposed to influence early bone development by downregulating CART, thereby reducing

osteoclast activity and increasing trabecular bone formation [23]. Influenced and adapted from

[1,2].

ATRX also participates in the resolution of G4 and R-loop structures. Although the exact

mechanism of action is unclear, ATRX has been proposed to act directly or exert secondary

effects that facilitate homologous recombination (HR)-mediated resolution of secondary

structures. ATRX has also been proposed to inhibit the formation of secondary structures by

sequestering free TERRA [1,2,24,25]. When ATRX function is disrupted, its silencing activity is

lost, resulting in elevated EZH2 and MRN activity at target sites and reduced suppression of

ATRX/DAXX-regulated regions. This deregulation promotes aberrant transcription [8].

Examination of the genetic factors influencing tumour initiation and progression has

long been a central focus of oncology research (Table 1). Deleterious mutations disrupting ATRX

function are frequently observed among several tumour types (Fig 3). ATRX mutations have

been most frequently linked to the development of the alternative lengthening of telomeres

(ALT) pathway, a telomerase-independent mechanism that confers replicative immortality on

cancer cells [19]. Mutations affecting the DAXX and SDT-like domains promote the formation of

ALT-associated PML-NBs (APBs), characteristic of ALT-positive cells. Unlike PML-NBs, APBs

localize at normally silent repetitive regions, driving aberrant transcription of telomeric and

pericentric sequences normally silenced by ATRX. Consequently, telomere sister chromatid

exchanges (T-SCEs), extrachromosomal telomeric C-circles, and TERRA-driven G4 and R-loop

structures become more prevalent, increasing the frequency of stalled replication forks. Since

ATRX also participates in replication fork repair, ALT-positive cells exhibit higher rates of

replication fork collapse and greater reliance on non-homologous end-joining (NHEJ), elevating

mutation rates and genomic instability [1–3].

Loss of ATRX function correlates with increased ALT activation in melanomas and

sarcomas, conferring heightened proliferative capacity and poorer disease-free survival [1,26–

28]. Somatic ATRX mutations are also associated with reduced disease-free survival, elevated

genomic instability, and increased tumor mutation burden in gliomas and pancreatic

neuroendocrine tumors (PanNETs)[29–31]. In gliomas, ATRX dysfunction compromises cell-cycle

checkpoints, fosters immune evasion, and worsens survival outcomes (Fig 3) [16,32]. Notably,

metastatic progression of pheochromocytomas and paragangliomas (PPGLs) have been

associated with ATRX mutations, which are among the most frequent gene-level events driving

PPGL metastatic potential [17,33,34]. Reflecting these findings, the fifth edition of the WHO

classification of Tumours of the Central Nervous System (2021) includes ATRX status as part of

the recommended diagnostic workup for gliomas. Recent studies in PanNETs have shown that

ATRX inactivation correlates with shorter disease-free intervals, more frequent ALT activation,

and increased mortality [30,31,35,36]. Mutations in ATRX, DAXX, and MEN1 (A-D-M mutants)

are particularly detrimental, leading to poorer prognoses and lower disease-free survival, with

or without ALT phenotype progression. One proposed mechanism involves hypermethylation of

CpG islands and subsequent repression of *PDX1*, driving beta pancreatic cells toward an alpha

lineage, which is correlated to worse clinical outcomes (Fig 3) [22]. The frequency of ATRX

mutations and their correlation to poor prognoses have spurred further exploration of the role

of ATRX in PanNETs.

Table 1. Reviews of ATRX in Other Tumours

Author	Year	Tumour Type	ATRX Status Examined	Effect of ATRX on Outcor
Gonzales-Céspedes (Navarro)[37]	2025	Neuroblastoma	Loss	Poor outcomes: very low surviv
Boehm (Tothill)[38]	2024	Phaeochromocytoma and paraganglioma	Loss	Poor outcomes: ALT, G2M cell cycle lncRNA dysregulation Good outcomes: increased sensitivity t
Levine (Hawkins)[39]	2024	Pediatric low-grade glioma	Loss	Poor outcomes: aggressive be
O'Neill (Rodriguez-Galindo)[40]	2024	Pediatric adrenocortical carcinoma	Loss	Poor outcomes
Sonnen (Brosen)[30]	2024	PanNENs	Loss	Poor outcomes: telomere dysfunction recurrence rate
Chang (Demirci)[26]	2023	Conjunctival Melanoma	Loss	Poor outcomes: ALT
Hackeng (Dreijerink)[41]	2023	Insulinoma	Loss	Poor outcomes: aggressive be

Haddox (Riedel)[42]	2023	Bone and soft tissue sarcoma	Loss	Good outcomes: increased sensitivi inhibitors
Luchini (Scarpa)[31,43]	2023	PanNENs	Loss	Poor outcomes: ALT, metastasis, tum
Metu (Rahman) [43]	2023	Astrocytoma	Loss	Poor outcomes: ALT Good outcomes: improved pro
Hackeng (Heaphy)[29]	2022	PanNETs	Loss	Poor outcomes: ALT, decreased rec survival
Ren (Li)[28]	2018	Sarcoma	Loss	Poor outcomes: ALT,
Karsy (Colman)[44]	2017	Glioma	Loss	Poor outcomes: ALT, astrocytoma/olig classification

ALT = alternative lengthening of telomeres, PanNENs = pancreatic neuroendocrine neoplasms,

PanNETs = pancreatic neuroendocrine tumours

Interestingly, certain tumours with ATRX mutations exhibit heightened sensitivity to

immune-mediated therapies (Fig 3). Specifically, ATRX loss can activate IRF transcription factors,

leading to increased recruitment of CD4+ and CD3+ T-cells; however, concurrent IDH mutations

may obscure this immune sensitization [18]. ATRX disruption has also been observed to

enhance the cytotoxic effects of temozolomide (TMZ) treatment in gliomas by reducing ATRX-

dependent inhibition of *FADD* transcription. FADD sequesters PARP from DNA, exposing the

genome to TMZ and increasing effectiveness of treatment. Loss of ATRX expression is thus

associated with increased susceptibility to radiation, chemotherapeutic agents, and

immunotherapies, positioning ATRX as a potential therapeutic target [2,20,21].

Pituitary neuroendocrine tumours (PitNETs), traditionally known as pituitary adenomas,

are common primary intracranial tumours of the adenohypophysis [45]. Like other

neuroendocrine tumours, PitNETs are classified based on hormonal secretion. Overproduction

and secretion of any adenohypophyseal hormones can cause debilitating effects associated

with conditions such as acromegaly and Cushing's disease. Although most clinically apparent

PitNETs are benign, approximately 10% exhibit aggressive and invasive behaviour, leading to

mass-effect symptoms from compression of adjacent intracranial structures [46,47]. Pituitary

neuroendocrine carcinomas (PitNECs), formally pituitary carcinomas (PCs), account for only 0.1-

0.5% of PitNET cases [46–50].   Metastases can occur in tumours that appear benign

histologically while other tumours that have histological features of aggressiveness can remain

isolated to the sellar region. Elevated mitotic activity and Ki-67 index scores are typically

associated with aggressive pituitary tumours (APTs) and PCs [48,51]. These tumours often resist

conventional surgical and radiotherapeutic interventions, with TMZ only showing moderate and

usually transient benefits in less than half of patients [50,52,53]. Survival data for APTs and PCs

indicate poor outcomes, with 3- and 5-year survival rates of 59% and 35%, respectively, and

median survival times of 17.2 and 11.3 years for patients who are responsive to TMZ [48,54].

Alterations in genes regulating chromatin and genome stability – such as *USP8, USP48, BRAF,*

GNAS, and SF3B1 – are frequently associated with worse prognoses and shorter progression-

free survival [55,56]. Despite various clinical and pathological markers, no definitive

histopathological feature can reliably predict the transition from a benign to an aggressive or

metastatic phenotype. Given the growing use of ATRX status as a prognostic marker in other

neuroendocrine tumors, it is essential to explore whether ATRX may similarly predict PitNET

aggressiveness and outcomes. The heightened susceptibility to mutagenesis and disrupted

transcriptional regulation observed in ATRX-deficient gliomas, sarcomas, and other

neuroendocrine tumours suggests that similar mechanisms could contribute to the aggressive

and proliferative behaviours seen in rare PitNET subtypes.

Currently, published data on the incidence of ATRX expression and its clinical

significance in neuroendocrine tumours, particularly PitNETs, is limited. The role of ATRX

protein expression in the prognosis of PitNETs remains unknown. In this systematic review, we

interpret the existing literature on ATRX expression in PitNETs to better describe its relationship

with the clinicopathological characteristics and prognosis of PitNET patients.

Methods

Search strategy

This systematic review was conducted following the Preferred Reporting Items for Systematic

Reviews and Meta-Analyses (PRISMA) guidelines. The aim was to identify all English published

studies on pituitary tumours exhibiting a loss of ATRX expression. The strategy involved

searching the PubMed, Embase, and Scopus databases to identify relevant studies published in

English from January 1, 2014 to March 1, 2025, using MeSH terms combined with free search

terms. A combination of the following keywords was used: ATRX, pituitary, pituitary adenoma,

pituitary carcinoma, alpha thalassemia X-linked, ATRX, PitNET. No other restrictions were

imposed, and no attempt was made to obtain unpublished results. All references and

supplementary data from all selected articles were also considered. The review was not

registered, nor was a review protocol prepared. All data collected and analyzed has been

reported in the manuscript.

Study selection

The selection of published material was conducted based on initial screening of titles or

abstracts followed by screening of full-text reviews. Manuscripts were considered eligible if they

met the following criteria: (i) the study was published in a peer-reviewed medical journal within

the last ten years, (ii) the study was published in English, (iii) the study described human case

studies involving pituitary tumours/PitNETs and ATRX, and (iv) the study observed a loss of ATRX

expression or mutation in the ATRX gene (Fig 4). Studies were omitted from review based on the

following exclusion criteria: (i) studies with publication types other than original research

articles, such as review articles, editorials, letters, commentaries, and conference abstracts.

Duplicate files were removed following export of database search results to Covidence. Risk of

bias assessments were evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal

Checklist for Studies Reporting Prevalence Data and the JBI Critical Appraisal Checklist for Case

Reports [57]. Quality assessment was not performed, and therefore no papers were excluded

due to poor quality.

Fig 4. Identification and selection of studies via databases.

Data extraction and quality assessment

Data was extracted from selected articles and included the following characteristics:

-    Study: year of publication, journal of publication, country, type of study

-    Sample Data: sample size, tumour type studied, mean age of participants at the time of

tumour resection, sex, evaluation strategies,

-    Study Results and Analysis: tumour classification, ALT status, Ki-67 index, identification

of other mutations within tumour sample

The analyzed data, including methods and results of each full-length publication, were reviewed

to satisfy the selection criteria and assess the quality of the text. No studies were excluded due

to poor quality of methods or unsatisfactory results. Results were independently extracted by

one author (EW) and assessed by another independent author (FR) to ensure accuracy and

inclusion of complete data. Any discrepancies were resolved by discussion.

Synthesis of data

All relevant patient demographics and tumour data were collected and tabulated in

Excel®. Tumours that were referred to as ACTH-secreting tumours, ACTH-omas, or exhibited T-

PIT expression were tabulated as corticotrophs. Null cell pituitary tumours were recorded as

nonfunctional pituitary adenomas. Similarly, gonadotrophs included tumours categorized by

LH/FSH secretion or SF1 expression. One study recorded gonadotrophs as nonfunctional

pituitary adenomas and did not specify the number of adenomas recorded [58]. Pit-1 lineage

tumours were further categorized into GH-secreting somatotroph and PRL-secreting lactotrophs

unless not stated. One study published following the change in pituitary tumour classification

also included acidophilic stem cell tumour classification, which was categorized as a lactotroph

based on hormone produced [59]. Thyrotrophs included TSH-secreting adenomas and

thyrotrophic adenomas. Any tumours that did not fall under these categories were tabulated

under "Other Tumour Type," including all plurihormonal tumours, pituitary carcinomas, and

pituitary rhabdomyosarcoma. Tumours labelled as metastatic PitNETs were categorized as

pituitary carcinomas for analysis. Tumours exhibiting ATRX within the included categories were

indicated within square brackets. Analytical techniques and evaluation strategies were indicated

in Table 2 while data that was unspecified or not measured was recorded in Table 3. The

statistical analysis included Fisher's exact test for associations between tumour recurrence, and

other tumour characteristics and ATRX loss. No other statistical or sensitivity analyses were

conducted.

Table 2. Characteristics of included publications examining the prevalence of ATRX loss in

human pituitary neuroendocrine tumours.

Author	Year	Journal	Country	Type of study	Sample size	Tumour Type	Evaluation Strategy	Loss of ATRX observed? (# if needed)
Casar-Borota (Trouillas)	2017	The American Journal of Surgical Pathology	Denmark	Case report & descriptive cross-sectional study	248	246 PitNET, 2 PC	IHC, NGS	Yes. 1 corticotropic pituitary carcinoma
Guo (Wang)	2018	Frontiers in Oncology	China	Case report & literature review	1	PC	IHC, NGS	Yes
Chen (Dahiya)	2019	Journal of Neuropathy and Experimental Neurology	United States of America	Descriptive cross-sectional study	42	Pediatric PA	IHC	Yes, 3 prolactinomas
Sbiera (Fassnach	2019	Neuro-oncology	Germany	Descriptive cross-	18	PA	WES, Sanger	Yes, 2 corticotroph

				sectional study			sequencing	s
Heaphy (Rodriguez)	2020	Modern Pathology	United States of America	Descriptive cross-sectional study	106	PA	IHC, FISH, WES, NGS	Yes, 1 case exhibited a loss of ATRX protein expression but no mutations in ATRX gene
Casar-Borota (Burman)	2021	The Journal of Clinical Endocrinology & Metabolism	Sweden	Descriptive cross-sectional study	47[a]	30 APT, 17 PC[a]	IHC, NGS	Yes, 8 cases (5 carcinomas): 6 corticotrophs (2 carcinomas 1, silent carcinoma, 3 adenomas), 1 lactotroph adenoma, 1 somato-lactotroph carcinoma[a]
Lu (Chen)	2021	Frontiers in Endocrinology	United States of America	Case report	1	Pituitary rhabdomyosarcoma arising from PA	NGS	Yes
Alzoubi (Buttarelli)	2022	Endocrine Pathology	Italy	Descriptive cross-sectional study	36	PA (24 adult recurrent + 12 primary pediatric)	IHC, FISH	Yes, 1 aggressive adult recurrent corticotroph tumour
Lamback (Gadelha)	2024	Journal of Clinical Endocrinology and Metabolism Case Reports	Brazil	Case report	1	PA	IHC	Yes, 1 null cell pituitary adenoma

| Terry (Perry) | 2024 | Endocrine Pathology | United States of America | Descriptive cross-sectional study | 13 | 7 metastatic PitNET, 5 PitNET | IHC, NGS | Yes, 1 silent corticotroph metastatic PitNET |

285 PitNET = pituitary neuroendocrine tumour, PC = pituitary carcinoma, PA = pituitary adenoma,

286 AP = aggressive pituitary tumour, IHC = immunohistochemical analysis, NGS = NextGen

287 sequencing, FISH = fluorescent in-situ telomere hybridization, WES = whole exome sequencing

288 [a] One patient was omitted from the sample, as it was repeated from Casar-Borota et al. (2017)

291 **Table 3. Demographic and clinical patient data examined in the included publications.**

Author (Date)	Average Age	Sex	Recurrent Tumour	Non-recurrent Tumour	Clinically Non-functional	Corticotroph	Somat
Casar-Borota (2017)	Unspecified [39]	Unspecified [F]	Unspecified	Unspecified	152	22	6
Guo (2018)	[55]	[M]	[1]	0	0	0	
Chen (2019)	17.64 [unspecified]	27 F, 15 M [2 F, 1 M]	5	37 [3]	9	9	
Sbiera (2019)	53.7 [52.5]	10 F, 8 M [2 F]	Unspecified	Unspecified	0	18	

Heaphy (2020)	53.4 [unspecified]	65 F, 41 M [unspecified]	18 [unspecified]	88 [unspecified]	83	1	1
Casar-Borota (2021)[c]	45 [45]	14 F, 33 M [2F, 6M]	47 [8]	0	1	10 [3]	
Lu (2021)	[77]	[M]	[1]	0	0	0	
Alzoubi (2022)	Adult: 52.9 Pediatric: 13 [Adult: 60]	Adult: 12 F, 12 M Pediatric: 9 F, 3 M [1 M]	24 adults [1 adult]	12 pediatric	0	6 adults + 2 pediatric [1 adult]	1 a
Lamback (2024)	63	[M]	[1]	0	[1]	0	
Terry (2024)	55 [65]	3 F, 10 M [M]	12 [1]	1	0	2	

Values in square brackets indicate samples with ATRX loss reported. ALT-positive = alternative-

lengthening of telomeres was present in the tumour sample

[a] Studies did not present data on length of follow-up for all subjects. Casar-Borota (2017)

described a 6-month follow-up period for one subject. Heaphy (2020) discussed a 2-year follow-

up period for one subject. Terry (2024) did not indicate a total length of follow-up but noted

that follow-up intervals ranged from 1 to 10 years.

[b] Information regarding tumour type and status were incomplete and could not be determined

[c] One pituitary carcinoma was excluded as the patient was shared with Casar-Borota (2017)

[d] 4 pituitary carcinomas exhibited ATRX loss (2 corticotrophs, 1 silent corticotroph, 1 somato-

lactotroph)

[e] Two of three specimens were collected from the tumour and evaluated separately for Ki-67

labelling index.

Potential for bias and risk of bias assessment

Preliminary screening was accomplished by one of the authors (EW) and then

reassessed by a second author (FR) according to the defined criteria to ensure that the same

data items were collected. The information was extracted from the full text independently by

each author. These efforts were directed toward conducting the analysis with minimal bias. Risk

of bias and quality assessments were determined using the Joanna Briggs Institute (JBI) Critical

Appraisal Checklist for Studies Reporting Prevalence Data (see Table 4) and the JBI Critical

Appraisal Checklist For Case Reports (see Table 5) [57].

 Table 4: Quality assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist

 for Prevalence Studies

	Casar-Borota (2017)	Chen (2019)	Sbiera (2019)	Heaphy (2020)	Casar-Borota (2021)	Alzoubi (2022)	Terry (2024)
Was the sample frame appropriate to address the target population?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Were study participants sampled in an appropriate way?	No	Yes	No	No	Yes	Yes	Yes
Was the sample size adequate?	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear	Unclear
Were the study subjects and the setting described in detail?	No	Yes	Yes	No	Yes	Yes	Yes
Was the data analysis conducted with sufficient coverage of the identified sample?	Unclear	Yes	Yes	No	Yes	Yes	Yes
Were valid methods used for the identification of the condition?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was the condition measured in a standard, reliable way?	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Was there appropriate statistical analysis	No	Yes	Yes	Yes	No	Yes	Yes
Was the response rate adequate, and if not, was the low response rate managed appropriately?	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Final Scores	3/8	7/8	6/8	4/8	6/8	7/8	7/8

316 N/A = Not applicable; the checklist item was not applicable to the study design

317 Studies with final scores ≥6 are reported as "great" quality. Studies with final scores ≤4 are

318 reported as "poor" quality. Studies with final scores = 5 are reported as "moderate" quality.

321 **Table 5: The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Risk of Bias for Case**

322 **Reports that were identified**

	Casar-Borota (2017)	Guo (2018)	Lu (2021)	Lamback (2024)
Were patient's demographic characteristics clearly described?	Yes	Yes	Yes	Yes
Was the patient's history clearly described and presented as a timeline?	Yes	Yes	Yes	Yes
Was the current clinical condition of the patient on presentation clearly described?	Yes	Yes	Yes	Yes
Were diagnostic tests or assessment methods and the results clearly described?	Yes	Yes	Yes	Yes
Was the intervention(s) or treatment procedure(s) clearly described?	Yes	Yes	Yes	Yes
Was the post-intervention clinical condition clearly described?	Yes	Yes	No	Yes
Were adverse events (harms) or unanticipated events identified and described?	Unclear	Yes	Unclear	Yes
Does the case report provide takeaway lessons?	Yes	Yes	Yes	Yes
Final Score	7/8	8/8	6/8	8/8

323 Studies with final scores ≥6 are reported as "good" quality. Studies with final scores ≤4 are

324 reported as "poor" quality. Studies with final scores = 5 are reported as "moderate" quality.

Results

Description of studies

A total of 48 studies were identified from database search after duplicates were

removed. Following screening of titles and abstracts, 16 irrelevant studies were excluded. All 32

of the remaining studies were retrieved and assessed for inclusion. Of these, 22 publications

failed to meet our inclusion criteria and were subsequently excluded. Fourteen studies were

excluded due to wrong patient population, of which eleven studies did not examine samples

including PitNETs for ATRX expression and mutations, while three studies were excluded due to

ATRX mutations occurring outside of the pituitary tumour. Additionally, eight studies were

excluded due incorrect study design, as the studies lacked inclusion of novel cases.

Consequently, a total of ten publications were included based on the predetermined criteria

[58–67].

Quality assessments were conducted for the nine studies deemed eligible for inclusion in

our review study. Given that the selected descriptive cross-sectional studies were retrospective,

analyzing tissue samples and existing medical records, subject response rate was not applicable

and thus excluded from the risk of bias assessment. Accordingly, both case reports and

descriptive studies were evaluated using an 8-point scale across various checklist parameters

[57]. Of the ten human studies that analyzed the prevalence of ATRX loss in PitNETs, three

studies presented case reports of a novel case that exhibited ATRX loss, while six were

descriptive cross-sectional studies. One study presented both a novel case report and a

descriptive cross-sectional study and was evaluated under both quality assessments [58]. Of the

seven descriptive studies included in the review, 5/7 (71%) studies received "great" scores (≥6),

while 2/7 (29%) studies were categorized as "poor" quality (<4) [58,63]. All four case reports

received "great" scores. Nonetheless, because case reports generally focus on single patients

and thus have limited generalizability and application, they still represent the weakest form of

patient-based evidence (see Tables 4 and 5).

Table 2 summarizes the characteristics of the studies examined, including demographic

data, sample size, and evaluation strategies. All studies examined were published since 2017. A

study was published in each of Canada, China, Denmark, Germany, Italy, Sweden, and Brazil, and

four studies published in the USA. Nine studies conducted immunohistochemical analysis to

determine ATRX protein presence, while four studies conducted NextGen sequencing to

determine the presence and location of ATRX gene mutations. One study did not conduct either

immunohistochemical analysis or NextGen sequencing. Instead, the study examined selected

tumours using whole-exome sequencing and Sanger sequencing [62]. One study also conducted

NextGen sequencing to identify mutations in target genes, but did not report any sequencing

results for the tumour lacking ATRX expression [59].

As 7/10 (70%) of the studies were conducted on data collected prior to the change in

pituitary tumour classification, tumours in these studies were referred to as pituitary adenomas.

Five studies examined adult pituitary tumour patients [59,60,62,65,67], while one study

examined pediatric pituitary adenoma patients [61]. Three studies included both adult and

pediatric pituitary adenoma patients [63,64,66]. One study did not disclose the age range of the

patients included in their study [58]. In total, 26 pituitary carcinoma patients were also included

from four studies in addition to their pituitary adenoma patients [58–60,64]. Additionally, one

study presented a novel case study regarding a pituitary rhabdomyosarcoma arising from a

pituitary adenoma that was identified to have a mutation in ATRX [65].

Patient data from the studies were summarized in Table 3, including basic patient

information and tumour types. A total of 513 tumours were examined across the ten studies

included. 246 tumours were clinically non-functional adenomas, 84 somatotroph adenomas, 70

corticotroph adenomas, 51 lactotroph adenomas, 15 gonadotroph adenomas, 3 thyrotroph

adenomas, and 7 pituitary adenomas present with Pit-1. Several plurihormonal tumours were

also included and were described in Table 3. The studies also reported 27 pituitary carcinomas,

including 16 classified as corticotroph, 4 as lactotroph, 2 as somatotroph, 2 as null cell, 1 as

gonadotroph, and 1 as plurihormonal. It was noted that in 3 of the studies reviewed, data

involving age (average), sex, and tumour recurrence was incomplete [58,62,63]. Of the reported

ages, the weighted average age of patients was 52. Among the publications that included sex

distribution data, there were 148 female patients and 118 male patients. Additionally, 109

tumors were identified as recurrent, while 139 were classified as non-recurrent. However, data

on follow-up duration were incomplete, with only 5 out of 9 studies providing information on

length of follow-up for all subjects. Among these studies, reported follow-up periods ranged

from 1.2 to 36 years [60,61,64,65,67].

Histopathological data regarding all tumours exhibiting ATRX loss included in this review

were summarized in Table 6. Only 20/513 (3.9%) tumours exhibited ATRX loss, of which 12/20

(60%) tumours were classified as corticotrophs while 4/20 (20%) were classified as lactotrophs.

One study reported a loss of ATRX protein expression in one tumour and partial loss in four

other tumours, but did not describe the patient or tumour type of the tumours that exhibited

loss of ATRX protein expression [63]. Furthermore, the researchers sequenced only the tumour

sample that exhibited full loss of ATRX expression and did not reveal any ATRX genetic

abnormalities. They also did not evaluate further the four cases that showed partial loss, and no

information was provided regarding the extent of the loss, so they were not classified as ATRX-

negative tumors. 17/20 (85%) of the tumours lacking ATRX expression were collected from adult

patients, with the remaining three reported as pediatric cases [61].

Table 6. Demographic and histopathological characteristics of tumours exhibiting ATRX.

	Source	Tumour Classification	Age	Sex	Evaluation	Recurrence Status	ALT Status	Ki-67	Mutations Identified
Tumour 1	Casar-Borota (2017)	Corticotroph pituitary carcinoma	39	F	IHC, NGS	NA	NA	NA	c.134_5217del; p.D45-K2027del[a]
Tumour 2	Guo (2018)	Corticotroph pituitary carcinoma	55	M	IHC, NGS	+	NA	80%	unspecified ATRX mutation
Tumour 3[b]	Chen (2019)	Lactotroph	NA	F	IHC	-	NA	<3%	NA
Tumour 4[b]	Chen (2019)	Lactotroph	NA	F	IHC	-	NA	<3%	NA
Tumour 5[b]	Chen (2019)	Lactotroph	NA	M	IHC	-	NA	>3%	NA
Tumour 6	Sbiera (2019)	Corticotroph	56	F	WES	NA	NA	1-2%	c.622G>C; p.Asp208His
Tumour	Sbiera (2019)	Corticotroph	40	F	WES	NA	NA	5-	g.7577127C>A;

Tumour	Author (year)	Type	Age	Sex	Methods			%	Mutation
ur 7								6%	p.Glu271Ter
Tumour 8	Heaphy (2020)	NA	NA	NA	IHC, WES, FISH	NA	+	NA	no mutations in ATRX gene
Tumour 9	Casar-Borota (2021)	Corticotroph pituitary carcinoma	45c	M	IHC, NGS	+	NA	NA	c.748C>T; p.Arg250Ter
Tumour 10	Casar-Borota (2021)	Corticotroph pituitary carcinoma	45c	M	IHC, NGS	+	NA	NA	c.6679delG; p.Asp2227fs c.3583delA; p.Arg1195fs
Tumour 11	Casar-Borota (2021)	Corticotroph pituitary carcinoma	45c	F	IHC, NGS	+	NA	NA	c.4048_4049delGG; p.Gly1350fs c.6661G>T; p.Glu2221Ter
Tumour 12	Casar-Borota (2021)	Somato-lactotroph carcinoma	45c	M	IHC, NGS	+	NA	NA	c.595_6669del, p.N199-K2233del
Tumour 13	Casar-Borota (2021)	Corticotroph	45c	M	IHC, NGS	+	NA	NA	c.2422C>T, p.Arg808Ter
Tumour 14	Casar-Borota (2021)	Corticotroph	45c	M	IHC, NGS	+	NA	NA	c.839_840insCATG, p.Asn281Ter
Tumour 15	Casar-Borota (2021)	Silent corticotroph	45c	M	IHC, NGS	+	NA	NA	c.5938T>A,c.5939delC, p.Ser1980fs
Tumour 16	Casar-Borota (2021)	Lactotroph APT	45c	F	IHC, NGS	+	NA	NA	c.21_6699del, p.E8-K2233del
Tumour 17	Lu (2021)	Pituitary rhabdomyosarcoma arising from pituitary adenoma	77	M	NGS	+	NA	NA	c.5406dup, p.R1803Tfs*7
Tumour 18	Alzoubi (2022)	Corticotroph	60	M	IHC, FISH	+	+	1%	NA
Tumour 19	Lamback (2024)	Nonfunctional null-cell pituitary adenoma	63	M	IHC	+	NA	11%	NA
Tumour 20	Terry (2024)	Corticotroph pituitary carcinoma	65	M	IHC	+	NA	19%	NA

NA = Statistic was not reported or not made available, + = Status associated with column was

present, - = Status was evaluated but not present at the time of reporting, IHC =

immunohistochemical analysis, NGS = NextGen sequencing, FISH = fluorescent in-situ

hybridization, WES = whole exome sequencing

[a] Mutation was collected from Casar-Borota et al. (2021)

[b] The three lactotrophs in Chen (2019) reported to lack ATRX expression did not specify which

of the three cases exhibited a Ki-67 index > 3%.

[c] Only average age was reported for the 8 tumours reported to lack ATRX expression. Range of

ages was reported as 23-72

410   Two studies [63,65] reported the number of patients exhibiting the ALT phenotype, of

which a total of 14 cases were identified and only 2/14 (14%) tumours exhibited ATRX loss. 5/9

studies reported the presence of other mutations within ATRX-negative tumours, of which *TP53*

was the most frequently reported mutation (10/18). One study investigated the presence of 20

common glioma mutations, including IDH1, IDH2, and ATRX, within the analyzed pituitary

tumours, of which 1/248 tumours exhibited a loss of ATRX due to a large deletion within the

gene [58]. It was not specified, however, what the other 17 mutations the tumour was screened

for or if any other mutations were observed. Ki-67 index was also reported by six studies [59–

62,66,67] with different parameters, in which two studies reported proliferation indices greater

than 3% as elevated [61,62], whereas another study reported indices greater than 2% as

elevated [66]. One study reported an increase in their Ki-67 index by 80% from a prior

examination but did not disclose what the absolute values were [60]. One study also reported

indices greater than 10% as a marker of high proliferation but did not specify what they

determined to be the threshold for an elevated index [67]. Various Ki-67 index thresholds for

prognostic significance have been reported in the literature, generally ranging between 1% and

10%; hence, all thresholds utilized by the reviewed studies fall within the recognized prognostic

range [68]. One study investigated aggressive pituitary adenomas and pituitary carcinomas,

which were both characterized by increased proliferation [64].

Of the 26 pituitary carcinomas included in the review, 7/26 (27%) exhibited a loss of

ATRX expression. 6/7 (86%) carcinomas with ATRX loss were corticotroph in nature while 1/7

(14%) presented as a somato-lactotroph. The remaining 19 pituitary carcinomas consisted of

10/19 (53%) reported to be corticotroph in nature, 3/19 (16%) as lactotroph in nature, and 2/19

(11%) as somatotroph in nature. The average age of pituitary carcinoma patients was between

16 and 73, with an average age of 46.1. Unfortunately, average age of carcinomas exhibiting

ATRX loss cannot be calculated due to incomplete reporting by one study [64]. All carcinomas

exhibited aggressive and transformative properties concomitant with their diagnosis, including

elevated proliferative growth, need for repeated surgical procedures, resistance to drug

therapies, and development of metastases. None of the studies that included pituitary

carcinomas examined the presence of the ALT phenotype. Only two of the studies that

presented pituitary carcinoma patients reported Ki-67 indices [59,60]. One study collected Ki-67

indices for two samples of the same tumour, recording 5% and 19% scores [59]. The second

study reported an increase by 80% from a previous examination but did not provide information

regarding the absolute value itself [60].

In the analysis of the relationship between ATRX loss and tumour recurrence [Table 7A],

tumour hormone secretion [Table 7B], and patient sex [Table 7C], one study was excluded due

to incomplete data regarding tumour recurrence, tumour type, and sex of patients with ATRX

loss [63]. Two other studies were excluded from tumour recurrence and sex analysis due to

incomplete reporting on the two parameters [58,62]. We did not find any significant

relationship between loss of ATRX expression and tumour recurrence status [Table 7A]. Sex was

also not a significant factor in ATRX expression [Table 7C]. However, tumour type was associated

with ATRX expression status. As described in Table 7B, the proportion of ACTH-secreting

tumours (corticotroph adenomas and corticotrophic pituitary carcinomas) exhibiting loss of

ATRX expression was significantly different from the proportion of other tumours that exhibited

ATRX loss (p < 0.0005). No other significant associations were observed.

Table 7. Fisher's exact tests comparing ATRX expression status and tumour recurrence (A),

tumour hormone secretion type (B), and sex of patient (C).

A	Status of ATRX Expression			
Tumour Recurrence[a]	ATRX Loss	ATRX Intact	Total	p-value
Recurrent	13	78	91	0.078
Non-recurrent	3	47	50	
Total	16	125	141	

B	Status of ATRX Expression			
Tumour Hormone Secretion[b]	ATRX Loss	ATRX Intact	Total	p-value
ACTH	12	75	87	5.52E-05*
Other	7	313	320	
Total	19	388	407	

C	Status of ATRX Expression			
Sex[c]	ATRX Loss	ATRX Intact	Total	p-value
Male	11	72	83	0.146
Female	7	69	76	
Total	18	141	159	

* Indicates significant p-value (*p < 0.05*)

ᵃ Casar-Borota et al. (2017), Sbiera et al. (2019), and Heaphy et al. (2020) were excluded due to

incomplete data reporting regarding tumour recurrence status

ᵇ Heaphy et al. (2020) was excluded due to incomplete data reporting regarding tumour type.

The nonfunctional case presented by Lamback et al. (2024) was included under "Other".

ᶜ Casar-Borota et al. (2017) and Heaphy et al. (2020) were excluded due to incomplete data

reporting regarding patient sex

Discussion

In the current study, we reviewed all available literature on ATRX expression in PitNETs.

Our analysis revealed a loss of ATRX expression in approximately 3.9% of the 513 cases that

were studied. Although ATRX is rarely mutated within PitNETs, patients with functioning

PitNETs, especially corticotrophs, are over-represented ($p < 0.0005$).

We observed ATRX loss in 4 PitNETs exhibiting the ALT phenotype. However, not all ALT-

positive tumours exhibited ATRX loss, suggesting that ATRX loss is not required for the ALT

phenotype to progress within the PitNETs studied. ATRX-independent ALT phenotype

progression has been observed in other tumour types, supporting this observation [69].

However, the limited examination of ALT among included studies limits further examination of

this observation. While ATRX loss has been strongly associated with the ALT phenotype in

tumour types such as gliomas and pancreatic tumours, we cannot determine a relationship

between ATRX function and the progression of the ALT phenotype in PitNETs from currently

published data.

Given ATRX's critical role in sustaining methylation of repetitive DNA regions, a loss of

ATRX expression may lead to errors in DNA replication and transcription during cell division.

Coupled with an increased propensity for the development of the ALT phenotype, impaired

ATRX function may promote the aberrant proliferative and transformative qualities in PitNETs

observed in the analysis. Similar trends have also been identified in PanNETs, where the loss of

ATRX/DAXX expression is associated with an increased propensity for proliferative development

and poor survival [35].   All studies reviewed here consistently reported an increase in

proliferative or transformative properties in tumours lacking ATRX expression. Four studies

reported an elevated incidence of ATRX loss in recurrent or aggressive PitNETs, both of which

presented with elevated proliferative traits [63,64,66,67]. However, given the multitude of

factors, including initial degree of tumour resection and tumour location, the data we collected

and analyzed from the publications demonstrated a non-significant trend with ATRX loss and

recurrence in PitNETs.

Detailed mutation information was available for only 12 of 20 tumours lacking ATRX

expression, with 11 cases exhibiting large mutations disrupting multiple domains of the ATRX

protein, including frameshifts, early terminations, and extensive deletions. These broad

mutations potentially disrupt ATRX-associated pathways, including PRC2- and PML-mediated

chromatin regulation processes. Additionally, impaired ATRX-mediated sequestration of MRN

complexes and compromised regulation of DNA damage responses may further increase

susceptibility to mutations in other tumour suppressor genes or oncogenes, thereby driving

aggressive and transformative tumour characteristics in the PitNETs discussed in this review.

Loss of ATRX expression was also noted in 27% of the 26 pituitary carcinomas presented

across the studies included in this review. Pituitary carcinomas exhibit significant proliferative

and transformative properties. The elevated prevalence of ATRX mutations among pituitary

carcinomas supports the proposed association between ATRX loss and increased propensity for

aggressive and proliferative development of tumours. It was also identified that 86% of the

ATRX-negative carcinomas were corticotroph in nature, similar to the trends identified in the

data from other ATRX-negative pituitary tumours collected in the review. However, as

corticotrophic carcinomas were overrepresented across the samples, making up over 60% of all

reported pituitary carcinomas, it is difficult to draw any conclusions from this observation. It is

also important to note that in one excluded study, a pituitary carcinoma was found to exhibit

ATRX mutations and expression loss in a liver metastasis but not in the original tumour,

highlighting the potential for pituitary carcinomas to gain ATRX mutations [70].

It is worth noting that mutations in TP53, a well-established tumour suppressor gene,

were identified in 50% of tumours exhibiting ATRX loss in the current review. As one of the most

frequently mutated genes in cancer, TP53 mutants have a well-established association with

proliferative development [71]. Notably, TP53 mutations have been proposed as markers to

distinguish neuroendocrine carcinomas from other neuroendocrine neoplasms [72]. Concurrent

mutations in TP53 and ATRX have been frequently observed in gliomas and sarcomas, with

several studies suggesting the combination of these mutations as prognostic indicators

associated with poorer survival outcomes [73,74]. The co-occurrence of TP53 and ATRX

mutations presents a significant challenge in isolating and specifically assessing the impact of

ATRX loss on the development and prognosis of PitNETs. Given the role of p53 in DNA repair and

tumour suppression, mutations in TP53 may increase the propensity for ATRX mutations,

thereby promoting proliferative development in pituitary tumours. Future studies may consider

investigating ATRX expression in PitNETs and the interplay with TP53 mutations in prognosis of

these patients.

All tumours exhibiting ATRX mutations and loss discussed in this review were identified

using either immunohistochemical analysis (IHC), next-generation sequencing (NGS), or a

combination of both. Although no studies have directly compared the effectiveness of NGS and

IHC in identifying and assessing ATRX loss in samples, both methods are well-established and

widely utilized in the field. The use of IHC for pathological analysis is a standard practice for

endocrine and neurological tumour diagnoses as a relatively inexpensive means of detecting

changes in protein expression. As ATRX mutations commonly result in truncated proteins, IHC is

used to identify loss of ATRX protein expression common in several tumour types [75,76].

However, certain ATRX mutations have been found to result in false ATRX positivity during IHC

due to positive staining for protein expression despite loss in protein function [77]. As IHC is

limited by the antibodies available for detection, unusual mutations can limit the accuracy and

effectiveness of such analyses for ATRX mutations. Furthermore, there is also a lack of

standardization regarding determination of ATRX loss in tumours like gliomas, where specific

thresholds for positive ATRX expression detected by IHC are not well enforced and vary between

studies [78]. NGS allows for more comprehensive detection of tumour mutations and can detect

multiple mutations across many genes in a single analysis. However, NGS is more costly and

time intensive, making it less accessible [79]. NGS may also miss mutations outside of the gene

that are impairing ATRX expression. Heaphy et al. identified a loss of ATRX expression in one

case by IHC but did not identify any mutations from NGS, suggesting an external mechanism

affecting ATRX expression [63]. A combination of IHC and NGS should be applied to provide

comprehensive tumour examination. Three studies also used a combination of IHC,

fluorescence in-situ hybridization (FISH), and whole exome sequencing (WES) for detection of

ATRX mutations [62,63,66]. While FISH offers a cost-effective means of detecting large

mutations, it is not sensitive enough to detect small intergenic changes that may affect ATRX

expression [79]. WES applies similar practices to NGS, but instead examines a sample's entire

exome sequence, leading to far higher costs and time detection [77]. Thus, both FISH and WES

are not as effective for frequent detection of ATRX mutations in PitNETs.

Limitations

The aim of this study was to review all published research on ATRX mutation and

expression in pituitary neuroendocrine tumours. To do so we must accept that we are limited to

the type and quality of the published articles from other leading researchers within the field.

With regards to our study, we found that the main limitation we identified was the

heterogeneity in reporting of results, hampering the ability to perform analyses regarding

outcome. For example, one study [63] did not report the tumour type or demographic data of

the tumours exhibiting ATRX expression loss, while two other studies [58,62] did not report the

average age, sex, and tumour recurrence status of patients in the study. Information regarding

duration of follow-up following prognosis and treatment were also incomplete across the study

reported in this review. Six studies reported varying follow-up periods between 6 months to 27

years, with many limited by patient loss and time between evaluation and publication [59–

61,64,65,67]. Two studies also reported on the recurrent tumour characteristics and did not

describe any evaluations of ATRX expression in the initial tumour [63,66]. Two studies did not

present follow-up reports and data of the pituitary tumours [58,62]. The limited data presented

regarding past visits and follow-up periods for patients included in each study hinders

investigations on links to aggressive behaviour and recurrence. As a diagnostic marker of

aggressive behaviour is recurrence, limited reporting and length of follow-up results may be

omitting potential tumours exhibiting ATRX loss.

Measurement variability also limited investigations, as the included studies used

different parameter thresholds for evaluation. The lack of a standard for declaring ATRX loss and

the limited reporting on thresholds used during IHC affect the validity of IHC evaluations of

ATRX loss. Furthermore, reporting on proliferative markers like Ki-67 were inconsistent, with

varied standards for elevated values. As mentioned earlier, two studies reported elevated Ki-67

as values greater than 3% [61,62], while one study reported values greater than 2% as being

elevated [66]. The inconsistent reporting of measurements limited any analyses and

investigations. Evaluation of reported measures was also limited. While co-occuring mutations

were observed and reported among tumours exhibiting ATRX loss, no further analyses were

conducted to examine whether any other mutations affected tumour outcomes and

measurements. Additionally, the limited research available regarding ATRX expression loss in

pituitary tumours further restricted the statistical power of the review, as very few centres were

involved in the collection of pituitary tumour samples used in the eight studies examined in the

review. As most patients were collected from neurosurgical centres, patient data may be biased

towards more severe and aggressive tumour cases.

Future research

Our literature search revealed that all identified studies were published since 2017,

highlighting this as an emerging field that requires further investigation. By comparing larger

cohorts of PitNETs with ATRX loss to those with intact ATRX function, along with adequate long-

term follow-up on outcomes, we can better understand the clinical significance of ATRX loss in

PitNETs. Multivariate analyses of ATRX mutations against other observed mutations like TP53

will assist in isolating the effects of ATRX mutations on PitNET progression. Molecular analyses

focused on ATRX-related pathways in ATRX-deficient PitNETs may also reveal deeper insights

into the specific consequences of ATRX loss.

Conclusions

Both ATRX loss and mutations are uncommon in PitNETs but when they do occur, they

primarily affect functional tumours, particularly those of corticotroph nature. Furthermore,

tumours lacking ATRX expression exhibit increased proliferative or transformative

characteristics, including a higher incidence of ATRX loss in pituitary carcinomas. Although ATRX

is associated with ALT phenotype repression, its loss was not found to exclusively dictate ALT

phenotype occurrence, suggesting a more complex relationship between ATRX expression and

ALT phenotype activation in PitNETs. This is an emerging area of study, and larger, prospective

studies with long follow-up and consistent reporting are crucial to further investigate the

implications of ATRX expression loss in PitNETs.

Data Availability

610 All data for this study were obtained from publicly available sources cited in the manuscript.

611 Extracted and summarized data supporting the findings of this study are included within the

612 manuscript and Supporting Information files. No new data was generated.

Acknowledgment

615 Authors are grateful to the Lloyd Carr-Harris Foundation for their continuous support.

References

1.   Yuan K, Tang Y, Ding Z, Peng L, Zeng J, Wu H, et al. Mutant ATRX: pathogenesis of ATRX

syndrome and cancer. Front Mol Biosci. 2024;11. doi:10.3389/fmolb.2024.1434398

2.   Aguilera P, López-Contreras AJ. ATRX, a guardian of chromatin. Trends in Genetics.

2023;39: 505–519. doi:10.1016/j.tig.2023.02.009

3.   Goncalves T, Bhatnagar H, Cunniffe S, Gibbons RJ, Rose AM, Clynes D. Phosphorylation of

'SDT-like' motifs in ATRX mediates its interaction with the MRN complex and is important

for ALT pathway suppression. Open Biol. 2024;14. doi:10.1098/rsob.240205

4.   Corpet A, Kleijwegt C, Roubille S, Juillard F, Jacquet K, Texier P, et al. PML nuclear bodies

and chromatin dynamics: catch me if you can! Nucleic Acids Res. 2020;48: 11890–11912.

doi:10.1093/nar/gkaa828

5.   Valenzuela M, Amato R, Sgura A, Antoccia A, Berardinelli F. The Multiple Facets of ATRX

Protein. Cancers (Basel). 2021;13: 2211. doi:10.3390/cancers13092211

6.   Xue Y, Gibbons R, Yan Z, Yang D, McDowell TL, Sechi S, et al. The ATRX syndrome protein

forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic

leukemia nuclear bodies. Proceedings of the National Academy of Sciences. 2003;100:

10635–10640. doi:10.1073/pnas.1937626100

7.   Voon HPJ, Wong LH. New players in heterochromatin silencing: histone variant H3.3 and

the ATRX/DAXX chaperone. Nucleic Acids Res. 2016;44: 1496–1501.

doi:10.1093/nar/gkw012

8.   Iwase S, Xiang B, Ghosh S, Ren T, Lewis PW, Cochrane JC, et al. ATRX ADD domain links an

atypical histone methylation recognition mechanism to human mental-retardation

syndrome. Nat Struct Mol Biol. 2011;18: 769–76. doi:10.1038/nsmb.2062

9.   Eustermann S, Yang J-C, Law MJ, Amos R, Chapman LM, Jelinska C, et al. Combinatorial

readout of histone H3 modifications specifies localization of ATRX to heterochromatin.

Nat Struct Mol Biol. 2011;18: 777–782. doi:10.1038/nsmb.2070

10.   Gibbons RJ, Picketts DJ, Villard L, Higgs DR. Mutations in a putative global transcriptional

regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome). Cell.

1995;80: 837–845. doi:10.1016/0092-8674(95)90287-2

11.   Gibbons RJ, Pellagatti A, Garrick D, Wood WG, Malik N, Ayyub H, et al. Identification of

acquired somatic mutations in the gene encoding chromatin-remodeling factor ATRX in

the α-thalassemia myelodysplasia syndrome (ATMDS). Nat Genet. 2003;34: 446–449.

doi:10.1038/ng1213

12.   Nguyen PC, Tiong IS, Westerman DA, Blombery P. A novel *ATRX* variant with splicing

consequences in myelodysplastic syndrome with acquired alpha thalassaemia. Br J

Haematol. 2023;200. doi:10.1111/bjh.18525

13.   Roake CM, Artandi SE. Keeping It in the Family: ATRX Loss Promotes Persistent Sister

Telomere Cohesion in ALT Cancer Cells. Cancer Cell. 2015;28: 277–279.

doi:10.1016/j.ccell.2015.08.005

14.   Scott WA, Dhanji EZ, Dyakov BJA, Dreseris ES, Asa JS, Grange LJ, et al. ATRX proximal

protein associations boast roles beyond histone deposition. PLoS Genet. 2021;17:

e1009909. doi:10.1371/journal.pgen.1009909

15.   Teng Y-C, Sundaresan A, O'Hara R, Gant VU, Li M, Martire S, et al. ATRX promotes

heterochromatin formation to protect cells from G-quadruplex DNA-mediated stress. Nat

Commun. 2021;12: 3887. doi:10.1038/s41467-021-24206-5

16.   Nandakumar P, Mansouri A, Das S. The Role of ATRX in Glioma Biology. Front Oncol.

2017;7. doi:10.3389/fonc.2017.00236

17.   Tothill R, Flynn A, Pattison A, Balachander S, Boehm E, Bowen B, et al. Multi-omic analysis

of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and

treatment-related molecular profiles. 2024. doi:10.21203/rs.3.rs-4410500/v1

18.   Hariharan S, Whitfield BT, Pirozzi CJ, Waitkus MS, Brown MC, Bowie ML, et al. Interplay

668   between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.

669   Nat Commun. 2024;15: 730. doi:10.1038/s41467-024-44932-w

670   19.   Darmusey L, Pérot G, Thébault N, Le Guellec S, Desplat N, Gaston L, et al. ATRX Alteration

671   Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas. Cancers

672   (Basel). 2021;13: 2151. doi:10.3390/cancers13092151

673   20.   Han B, Meng X, Wu P, Li Z, Li S, Zhang Y, et al. ATRX/EZH2 complex epigenetically regulates

674   FADD/PARP1 axis, contributing to TMZ resistance in glioma. Theranostics. 2020;10: 3351–

675   3365. doi:10.7150/thno.41219

676   21.   Xie Y, Wang H, Wang S, Feng Y, Feng Y, Fan S, et al. Clinicopathological Significance of ATRX

677   Expression in Nasopharyngeal Carcinoma Patients: A Retrospective Study. J Cancer.

678   2021;12: 6931–6936. doi:10.7150/jca.63333

679   22.   Chan CS, Laddha S V., Lewis PW, Koletsky MS, Robzyk K, Da Silva E, et al. ATRX, DAXX or

680   MEN1 mutant pancreatic neuroendocrine tumors are a distinct alpha-cell signature

681   subgroup. Nat Commun. 2018;9: 4158. doi:10.1038/s41467-018-06498-2

682   23.   Chen Y-T, Jiang M-M, Leynes C, Adeyeye M, Majano CF, Ibrahim B, et al. ATRX silences

683   Cartpt expression in osteoblastic cells during skeletal development. Journal of Clinical

684   Investigation. 2025;135. doi:10.1172/JCI163587

685   24.   Clynes D, Jelinska C, Xella B, Ayyub H, Scott C, Mitson M, et al. Suppression of the

686   alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.

687   Nat Commun. 2015;6: 7538. doi:10.1038/ncomms8538

25.   Raghunandan M, Yeo JE, Walter R, Saito K, Harvey AJ, Ittershagen S, et al. Functional cross

talk between the Fanconi anemia and ATRX/DAXX histone chaperone pathways promotes

replication fork recovery. Hum Mol Genet. 2020;29: 1083–1095.

doi:10.1093/hmg/ddz250

26.   Chang E, Demirci H, Demirci FY. Genetic Aspects of Conjunctival Melanoma: A Review.

Genes (Basel). 2023;14: 1668. doi:10.3390/genes14091668

27.   Lally SE, Milman T, Orloff M, Dalvin LA, Eberhart CG, Heaphy CM, et al. Mutational

Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology.

2022;129: 679–693. doi:10.1016/j.ophtha.2022.01.016

28.   Ren X, Tu C, Tang Z, Ma R, Li Z. Alternative lengthening of telomeres phenotype and loss

of ATRX expression in sarcomas (Review). Oncol Lett. 2018. doi:10.3892/ol.2018.8318

29.   Hackeng WM, Assi HA, Westerbeke FHM, Brosens LAA, Heaphy CM. Prognostic and

Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surg Pathol Clin. 2022;15:

541–554. doi:10.1016/j.path.2022.05.007

30.   Sonnen AF-P, Verschuur AVD, Brosens LAA. Diagnostic and prognostic biomarkers for

pancreatic neuroendocrine neoplasms. Die Pathologie. 2024;45: 74–82.

doi:10.1007/s00292-024-01393-8

31.   Luchini C, Scarpa A. Neoplastic Progression in Neuroendocrine Neoplasms of the

Pancreas. Arch Pathol Lab Med. 2024;148: 975–979. doi:10.5858/arpa.2022-0417-RA

32.   Hu C, Wang K, Damon C, Fu Y, Ma T, Kratz L, et al. ATRX loss promotes immunosuppressive

mechanisms in IDH1 mutant glioma. Neuro Oncol. 2022;24: 888–900.

doi:10.1093/neuonc/noab292

33.   Calsina B, Piñeiro-Yáñez E, Martínez-Montes ÁM, Caleiras E, Fernández-Sanromán Á,

Monteagudo M, et al. Genomic and immune landscape Of metastatic

pheochromocytoma and paraganglioma. Nat Commun. 2023;14: 1122.

doi:10.1038/s41467-023-36769-6

34.   Job S, Draskovic I, Burnichon N, Buffet A, Cros J, Lépine C, et al. Telomerase Activation and

ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and

Paraganglioma. Clinical Cancer Research. 2019;25: 760–770. doi:10.1158/1078-0432.CCR-

18-0139

35.   Singhi AD, Liu T-C, Roncaioli JL, Cao D, Zeh HJ, Zureikat AH, et al. Alternative Lengthening

of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor

Survival in Patients with Pancreatic Neuroendocrine Tumors. Clinical Cancer Research.

2017;23: 600–609. doi:10.1158/1078-0432.CCR-16-1113

36.   Hackeng WM, Brosens LAA, Kim JY, O'Sullivan R, Sung Y-N, Liu T-C, et al. Non-functional

pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of

telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour

size. Gut. 2022;71: 961–973. doi:10.1136/gutjnl-2020-322595

37.   Gonzales-Céspedes G, Navarro S. High-risk neuroblastoma: ATRX and TERT as prognostic

markers and therapeutic targets. Review and update on the topic. Revista Española de

Patología. 2025;58: 100790. doi:10.1016/j.patol.2024.100790

38.   Boehm E, Gill AJ, Clifton-Bligh R, Tothill RW. Recent progress in molecular classification of

phaeochromocytoma and paraganglioma. Best Pract Res Clin Endocrinol Metab. 2024;38:

101939. doi:10.1016/j.beem.2024.101939

39. Levine AB, Hawkins CE. Molecular markers for pediatric low-grade glioma. Child's

Nervous System. 2024;40: 3223–3228. doi:10.1007/s00381-024-06639-7

40. O'Neill A, Ribeiro R, Pinto E, Clay M, Zambetti G, Orr B, et al. Pediatric Adrenocortical

Carcinoma: The Nuts and Bolts of Diagnosis and Treatment and Avenues for Future

Discovery. Cancer Manag Res. 2024;Volume 16: 1141–1153. doi:10.2147/CMAR.S348725

41. Hackeng WM, Brosens LAA, Dreijerink KMA. Aggressive versus indolent insulinomas: new

clinicopathological insights. Endocr Relat Cancer. 2023;30. doi:10.1530/ERC-22-0321

42. Haddox CL, Riedel RF. Emerging predictive biomarkers in the management of bone and

soft tissue sarcomas. Expert Rev Anticancer Ther. 2023;23: 495–502.

doi:10.1080/14737140.2023.2200169

43. Nahar Metu CL, Sutihar SK, Sohel M, Zohora F, Hasan A, Miah MdT, et al. Unraveling the

signaling mechanism behind astrocytoma and possible therapeutics strategies: A

comprehensive review. Cancer Rep. 2023;6. doi:10.1002/cnr2.1889

44. Karsy M, Guan J, Cohen AL, Jensen RL, Colman H. New Molecular Considerations for

Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. Curr Neurol Neurosci Rep. 2017;17: 19.

doi:10.1007/s11910-017-0722-5

45. Asa SL, Mete O, Perry A, Osamura RY. Overview of the 2022 WHO Classification of

Pituitary Tumors. Endocr Pathol. 2022;33: 6–26. doi:10.1007/s12022-022-09703-7

46. Russ S, Anastasopoulou C, Shafiq I. Pituitary Adenoma. StatPearls; 2024.

47. Nishioka H. Aggressive pituitary tumors (PitNETs). Endocr J. 2023;70: EJ23-0007.

doi:10.1507/endocrj.EJ23-0007

48. Burman P, Trouillas J, Losa M, McCormack A, Petersenn S, Popovic V, et al. Aggressive

pituitary tumours and carcinomas, characteristics and management of 171 patients. Eur J

Endocrinol. 2022;187: 593–605. doi:10.1530/EJE-22-0440

49. Kasuki L, Raverot G. Definition and diagnosis of aggressive pituitary tumors. Rev Endocr

Metab Disord. 2020;21: 203–208. doi:10.1007/s11154-019-09531-x

50. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European

Society of Endocrinology Clinical Practice Guidelines for the management of aggressive

pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178: G1–G24. doi:10.1530/EJE-

17-0796

51. Lasolle H, Vasiljevic A, Jouanneau E, Ilie MD, Raverot G. Aggressive corticotroph tumors

and carcinomas. J Neuroendocrinol. 2022;34. doi:10.1111/jne.13169

52. Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, et al. Aggressive pituitary

tumours and pituitary carcinomas. Nat Rev Endocrinol. 2021;17: 671–684.

doi:10.1038/s41574-021-00550-w

53. McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al.

Treatment of aggressive pituitary tumours and carcinomas: results of a European Society

of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178: 265–276.

doi:10.1530/EJE-17-0933

54. Santos-Pinheiro F, Penas-Prado M, Kamiya-Matsuoka C, Waguespack SG, Mahajan A,

Brown PD, et al. Treatment and long-term outcomes in pituitary carcinoma: a cohort

study. Eur J Endocrinol. 2019;181: 397–407. doi:10.1530/EJE-18-0795

55.   Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, et al.

Mutations in the deubiquitinase gene USP8 cause Cushing's disease. Nat Genet. 2015;47:

31–38. doi:10.1038/ng.3166

56.   Spada A, Mantovani G, Lania AG, Treppiedi D, Mangili F, Catalano R, et al. Pituitary

Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical Behavior.

Neuroendocrinology. 2022;112: 15–33. doi:10.1159/000514862

57.   Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z. JBI Manual for Evidence Synthesis.

Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z, editors. JBI; 2024.

doi:10.46658/JBIMES-24-01

58.   Casar-Borota O, Botling J, Granberg D, Stigare J, Wikström J, Boldt HB, et al. Serotonin,

ATRX, and DAXX Expression in Pituitary Adenomas: Markers in the Differential Diagnosis

of Neuroendocrine Tumors of the Sellar Region. Am J Surg Pathol. 2017;41: 1238–1246.

doi:10.1097/PAS.0000000000000908

59.   Terry M, Nguyen MP, Tang V, Guney E, Bharani KL, Dahiya S, et al. High-Grade Progression,

Sarcomatous Transformation, and/or Metastasis of Pituitary Neuroendocrine Neoplasms

(PitNENs): The UCSF Experience. Endocr Pathol. 2024. doi:10.1007/s12022-024-09829-w

60.   Guo F, Wang G, Wang F, Xu D, Liu X. Identification of Novel Genes Involved in the

Pathogenesis of an ACTH-Secreting Pituitary Carcinoma: A Case Report and Literature

Review. Front Oncol. 2018;8: 510. doi:10.3389/fonc.2018.00510

61.   Chen J, Schmidt RE, Dahiya S. Pituitary Adenoma in Pediatric and Adolescent Populations.

J Neuropathol Exp Neurol. 2019;78: 626–632. doi:10.1093/jnen/nlz040

62.   Sbiera S, Perez-Rivas LG, Taranets L, Weigand I, Flitsch J, Graf E, et al. Driver mutations in

USP8 wild-type Cushing's disease. Neuro Oncol. 2019;21: 1273–1283.

doi:10.1093/neuonc/noz109

63.   Heaphy CM, Bi WL, Coy S, Davis C, Gallia GL, Santagata S, et al. Telomere length

alterations and ATRX/DAXX loss in pituitary adenomas. Mod Pathol. 2020;33: 1475–1481.

doi:10.1038/s41379-020-0523-2

64.   Casar-Borota O, Boldt HB, Engström BE, Andersen MS, Baussart B, Bengtsson D, et al.

Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX

Mutations. J Clin Endocrinol Metab. 2021;106: 1183–1194. doi:10.1210/clinem/dgaa749

65.   Lu J, Chen L. Molecular Profile of a Pituitary Rhabdomyosarcoma Arising From a Pituitary

Macroadenoma: A Case Report. Front Endocrinol (Lausanne). 2021;12: 752361.

doi:10.3389/fendo.2021.752361

66.   Alzoubi H, Minasi S, Gianno F, Antonelli M, Belardinilli F, Giangaspero F, et al. Alternative

Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter

Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Endocr Pathol. 2022;33: 494–505. doi:10.1007/s12022-021-09702-0

67.   Lamback E, Miranda RL, Ventura N, Chimelli L, Gadelha MR. Loss of ATRX Protein

Expression in an Aggressive Null Cell Pituitary Tumor. JCEM Case Reports. 2024;2.

doi:10.1210/jcemcr/luae143

68.   Chudasama P, Mughal SS, Sanders MA, Hübschmann D, Chung I, Deeg KI, et al. Integrative

genomic and transcriptomic analysis of leiomyosarcoma. Nat Commun. 2018;9.

doi:10.1038/s41467-017-02602-0

69.   Sumislawski P, Rotermund R, Klose S, Lautenbach A, Wefers AK, Soltwedel C, et al. ACTH-

secreting pituitary carcinoma with TP53, NF1, ATRX and PTEN mutations Case report and

review of the literature. Endocrine. 2022;76: 228–236. doi:10.1007/s12020-021-02954-0

70.   Olivier M, Hollstein M, Hainaut P. TP53 Mutations in Human Cancers: Origins,

Consequences, and Clinical Use. Cold Spring Harb Perspect Biol. 2010;2: a001008–

a001008. doi:10.1101/cshperspect.a001008

71.   Sun BL, Ding H, Sun X. Histopathologic and genetic distinction of well-differentiated grade

3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-

grade neuroendocrine neoplasms. Am J Clin Pathol. 2025. doi:10.1093/ajcp/aqaf013

72.   Crowell C, Mata-Mbemba D, Bennett J, Matheson K, Mackley M, Perreault S, et al.

Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and

associated clinical factors. Neurooncol Adv. 2022;4: vdac133.

doi:10.1093/noajnl/vdac133

73.   Dermawan JK, Chiang S, Singer S, Jadeja B, Hensley ML, Tap WD, et al. Developing Novel

Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma. Clinical

Cancer Research. 2024;30: 2260–2271. doi:10.1158/1078-0432.CCR-24-0148

74.   Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH, Shi C, et al. Altered Telomeres in Tumors

with *ATRX* and *DAXX* Mutations. Science (1979). 2011;333: 425–425.

doi:10.1126/science.1207313

75.   Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, et al. ATRX

loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH

mutant astrocytic tumors with better prognosis. Acta Neuropathol. 2013;126: 443–451.

doi:10.1007/s00401-013-1156-z

76. Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-

R132H immunohistochemistry with subsequent copy number analysis and IDH

sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma,

oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129: 133–146.

doi:10.1007/s00401-014-1370-3

77. Tanboon J, Williams EA, Louis DN. The Diagnostic Use of Immunohistochemical

Surrogates for Signature Molecular Genetic Alterations in Gliomas. J Neuropathol Exp

Neurol. 2016;75: 4–18. doi:10.1093/jnen/nlv009

78. Scheie D, Kufaishi HHA, Broholm H, Lund EL, de Stricker K, Melchior LC, et al. Biomarkers

in tumors of the central nervous system – a review. APMIS. 2019;127: 265–287.

doi:10.1111/apm.12916

Supporting Information

Figure S1. PRISMA 2020 Checklist